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ABSTRACT 
 
The Ras superfamily of GTPases are important regulators of morphogenesis involved in 
control of cytoskeletal dynamics, intracellular trafficking, apical-basal polarity and cell 
migration.  Mis-regulation of GTPase signaling interferes with development and is linked 
to pathogenesis.  Traditionally, GTPase signaling has been depicted as a series of 
independent linear pathways. However, recently it has become apparent that multiple 
GTPases can interact to regulate a single cellular process, functioning in poorly 
understood networks of cross talk between pathways during development.  Jim Fristrom 
(unpublished data) identified a mutation (18-5) that interacts with components of the 
GTPases Rho1, Rala, and Cdc42 signaling in multiple developmental contexts.  Genetic 
analysis, physical mapping studies, and sequencing of the mutant allele have indicated 
that the gene was an allele of GEFmeso (CG30115), which encodes guanine nucleotide 
exchange factor.  To show that 18-5 is an allele of GEFmeso, I demonstrated that a 
GEFmeso transgene could functionally rescue developmental defects associated with the 
18-5 mutation. I also investigated cross talk and network variation in signaling 
interactions between GEFmeso and other GTPase signaling components in the 
Drosophila wing. My data provide evidence for microenvironment-dependent variation in 
GTPase signaling networks in specific domains of the wing, and reveal intercellular 
variation in GTPase signaling within an otherwise uniform epithelium. 
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CHAPTER ONE: INTRODUCTION 
 
GTPase signaling and Principles of Regulation 
 
The Ras superfamily of small GTPases are ubiquitous, highly conserved proteins 
regulating proliferation, cell migration, morphogenesis and differentiation across many 
species.  GTPases accomplish these tasks by acting as key components linking 
extracellular signals to intracellular responses (Wennerberg et al, 2005; Hancock, 2003; 
Lindquist, 2006).  The Rho (Ras Homology) family of GTPases are a subfamily of the 
Ras superfamily, and the most well studied members in vertebrates are RhoA, Rac1 and 
Cdc42, regulating stress fiber, lamellipodia and filopodia formation, respectively 
(Wennerberg et al, 2005; Hancock, 2003).  Most members of the superfamily are cycled 
between active (GTP bound) and inactive (GDP bound) states by guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs).  Guanine dissociation 
factors (GDIs) stabilize and sequester GTPases in an inactive state (Wennerberg et al, 
2005; Boulter et al, 2010).  The active GTP-bound GTPase interacts with downstream 
effector proteins to trigger signaling cascades that elicit context-dependent cellular 
responses (Figure 1).  Mis-regulation of the signaling pathways controlled by these 
GTPases is associated with many forms of pathogenesis. 
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In the active GTP-bound state, GTPases interact with effectors to trigger cellular 
responses. 
 
Figure 1: Cycling of GTPases between active and inactive states is regulated by 
GEFs, GAPs and GDIs 
 
Epithelial Development and the Requirement for the Rho family of GTPases 
 
Epithelia create selectively permeable barriers, forming boundaries between body 
compartments and structures.  During developmental processes, epithelial tissues undergo 
extensive remodeling during developmental processes.  Establishment of cell polarity, 
directed cell migration, cell rearrangement and tissue morphogenesis are important 
developmental events. 
 
 
Polarization of cells within epithelia is often observed during organogenesis.  For 
example, the establishment of apical-basal polarity is a critical process required to 
properly form the lining of the gastrointestinal tract, and assembly of apical tight 
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junctions required in intestinal epithelia is a ROCK-dependent process (Walsh et al 
2001).  In Drosophila, each individual cell of the wing become polarized across a plane 
of the epithelium, forming a single distal-pointing hair per cell (Van Aelst and Symons, 
2002; Yan et al, 2009).  Aberrantly activated Rho1(Drosophila RhoA) or Cdc42 in the 
wing affects planar polarity, with phenotypes depending on the severity of the mutation 
such as shortened wing hairs, multiple wing hairs, or  no wing hairs (Baron et al, 2000; 
Winter et al, 2001; Yan et al, 2009). 
 
 
Directed cell migration is required for development and for physiological processes.  
Cells often must migrate either as individual cells or as part of an epithelial sheet to a 
new position.  During Drosophila embryonic development, epithelial sheets migrate 
dorsally in a Rho GTPase-dependent process, meeting in the midline and enclosing the 
animal (Harden, 2002).   
 
 
Morphogenesis requires a precisely coordinated series of cell behaviors including cell 
migration, cell rearrangements, and cell shape changes contributing to the final adult 
form.  For example, in Drosophila the final shape of the adult leg is dependent on cell 
shape changes driven by Rho1-dependent contraction of the actin-myosin belt (vonkalm 
et al, 1994; Halsell et al, 2000; Bayer et al, 2003; Condic et al, 1991).   Rho GTPases are 
also required during many aspects of neuronal development, such as myelination and 
neuronal migration (Luo, 2002; Park and Feltri, 2011). 
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GTPase Signaling and Pathology 
 
The Ras family of GTPases are frequently found to have hyperactive mutations in 
cancers (Pruitt and Der, 2001; Tidyman and Rauen, 2009).  However, of the Rho family 
of GTPases, RhoH is the only protein with a known mutation in human cancers.  
Frequently, the expression and activation levels are the main cause of a disease 
phenotype (Boettner and Van Aelst, 2002; Fritz et al, 2002).  Studies examining RhoA 
and Rac1 expression in cancer patients show upregulation in hepatocellular carcinomas 
and breast cancers when compared to healthy tissues (Fukui et al, 2006; Schnelzer et al, 
2000; Jordan et al, 1999).  In addition, malignant breast tissues have increased 
immunohistochemical staining for Rac1 when compared to non-malignant tissue 
(Schnelzer et al, 2000; Jordan et al, 1999).  Several other GTPases (RhoA, Rac1 and 
Cdc42) have elevated expression in tissues from patients with testicular cancer, and the 
expression level positively correlates with more advanced stages (Kamai et al, 2004; 
Kamai et al, 2002).  Similar correlations are observed when comparing RhoA protein 
levels in malignant and non-malignant breast tissue (Fritz et al, 2002). 
 
GTPase Signaling Exhibits Cross Talk and is Organized as a Network 
 
Traditionally, GTPase signaling was depicted as a linear chain of events where growth 
factors stimulate a GTPase leading to effector activation, and in turn inducing 
downstream effects such as stress fiber formation, focal adhesion, or membrane ruffling 
(Ridley and Hall, 1992; Burridge and Wennerberg, 2004).  However, in the past five to 
ten years it has become apparent that there is considerable cross talk among GTPase 
 5 
signaling pathways which can involve GTPase regulators, GTPases and their effector 
molecules (Pertz, 2010; Burridge and Wennerberg, 2004).  
 
 
Cross talk between GTPases is used to control the spatial distribution of GTPase 
regulators.  For example, Rap1 localizes the Vav2 GEF to pseudopodia in Hela cells 
during cell spreading where it activates Rac1 (Arthur et al, 2004).  In MDCK and Hela 
cells Rac1 localizes RhoGAPp190B to membrane ruffles where Rac1 promotes GAP 
activity and inhibits RhoA (Bustos et al, 2008). 
 
 
Post-translational modifications to one GTPase can also influence activation of another 
GTPase.  For example, in HEK293, Hela, and vascular smooth muscle cells, 
phosphorylation of RhoA displaces Rac1 from RhoGDI, leading to activation of Rac1 
(Boulter et al, 2010; Rolli-Derkinderen et al, 2010). 
 
 
The effector of one GTPase can also regulate the activity of an  effector of another 
GTPase.  For example, upon Ras stimulation in COS-1 cells and MEFs, Raf-1 (Ras 
effector) binds to and inhibits Rok-α (RhoA effector) (Ehrenreiter et al, 2005; Niault et al 
2009).  In human melanoma A7 cells and HEK293 cells, ROCK (RhoA effector) 
phosphorylates and activates FilGAP (negative regulator of Rac), resulting in membrane 
blebbing (Ohta et al, 2006).   In an added layer of complexity, it is apparent that some 
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regulators have the capacity to act as activators and repressors. For example, the Abr and 
Bcr proteins each contain activating Dbl and inactivating GAP domains, and can both 
positively and negatively regulate Rac and Cdc42 (Chuang et al, 1995).  
 
 
The evidence for crosstalk between GTPase signaling cascades has been well established; 
and crosstalk appears to be so extensive that the term ‘network’ may be a more accurate 
way to describe GTPase signaling pathway organization.  Currently, FRET and other 
techniques are being used to investigate GTPase organization within subcellular 
compartments, however little is known about how these networks operate and vary in 
vivo.  Investigations that study GTPase signaling networks in a range of developmental 
contexts are needed to provide a more accurate picture of the organization of  GTPase 
networks within and between tissues and their contributions to pathogenesis.  
 
GEFmeso: A Developmental Integrator of Multiple GTPase Signals in Multiple 
Tissues 
 
Our laboratory previously reported a genetic screen for mutations  that affect the Rho1 
(Drosophila RhoA) signaling pathway leading to activation of zipper (nonmuscle myosin 
II heavy chain) during leg and wing imaginal disc morphogenesis (Bayer et al, 2003).  
One allele identified in the screen, designated 18-5, was of special interest because it 
interacted with Rho1 and potentially encoded a novel member of the Rho1 signaling 
pathway.  18-5 homozygote adult escapers are rare and exhibit severe leg and wing 
malformations and an ectopic cross vein wing phenotype.  Subsequent work in our lab 
 7 
has shown that the 18-5 allele also interacts with Rho1 to control embryonic head 
involution and dorsal closure (Smallwood and von Kalm, unpublished observations).   
 
 
Genetic mapping experiments localized the 18-5 allele to a region of chromosome two, 
containing a putative guanine nucleotide exchange factor encoded by gene CG30115 
(Fox, 2006).  Blanke and Jackle (2006) characterized CG30115, which they named 
GEFmeso after identifying it in a yeast-two hybrid screen for proteins that bind to the 
DRala GTPase.  The GEFmeso gene encodes two protein products, designated long and 
short, which differ in the N-terminal region (Figure 2).  The GEFmeso short transcript is 
observed only in 0-3hr embryos.  GEFmeso long expression is first detected in 3 hr 
embryos and is thereafter continuously observed into adulthood (Blanke and Jackle, 
2006; Flybase).  
 
 
Red brackets indicate region of GEFmeso deleted by the 18-5 mutation.  Figure adapted 
from Blanke and Jackle, 2006 
 
Figure 2: Protein Domain Structure of GEFmeso Long and Short Proteins 
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In in vitro binding assays, GEFmeso binds to GTP-bound DRala and nucleotide-depleted 
Cdc42, but not to Rac, Mtl (a Drosophila Rac ortholog) or Rho1 (Blanke and Jackle, 
2006).  In addition, RNAi against GEFmeso in the wing results in an ectopic cross vein 
phenotype similar to the 18-5 homozygous mutant phenotype (Figure 3).  Sequencing of 
the CG30115/GEFmeso gene in 18-5 homozygotes revealed a 502-nucleotide deletion 
within the gene.  The deletion removes the last 52 amino acids of the pleckstrin 
homology domain and creates a frame shift that leads to premature termination of 
translation and loss of the Ral and PDZ binding motifs in the GEFmeso long protein 
(Morgan, Smallwood and von Kalm, unpublished observations; Figure 2).  The GEFmeso 
short transcript is not affected by the 18-5 deletion. 
   
 
 
Wing vein phenotypes of an 18-5 homozygote (left image) and GEFmeso RNAi targeted 
throughout the wing. Arrows indicate ectopic cross veins 
 
Figure 3 The 18-5 Homozygote Phenotype is Comparable to Phenotypes Observed 
in GEFmeso RNAi Animals 
 
Collectively, the data suggest that the 18-5 mutation is an allele of GEFmeso and that 
GEFmeso is an integrator of multiple signals coordinating GTPase activity during 
development.  GEFmeso interacts with multiple GTPases in biochemical (DRala and 
Cdc42; Blake and Jackle, 2006) and genetic contexts (Rho1 and Cdc42; Fox, 2006; Bayer 
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et al, 2003).  Moreover, the interactions occur in multiple cell types throughout 
embryonic and adult development, indicating that GEFmeso may be a global signal 
regulator/integrator for several GTPases.  Therefore, GEFmeso and its interacting 
partners are an ideal starting point to compare GTPase networks in similar developmental 
contexts.  
 
 I hypothesize that GEFmeso is a global regulator of GTPase network activity during 
Drosophila development.  To address this hypothesis, I examined the role of GEFmeso in 
a GTPase network in the developing wing, which is a simple epithelium consisting of 
vein and intervein cells.  Specifically, I identified interactions between GEFmeso and 
GTPases and their regulators in developing wing veins.  Wing vein development is well 
suited for these studies because it is a GTPase-dependent process with easily scored 
mutant phenotypes.  In addition, the wing is dispensable to survival allowing for the 
identification of interactions that might be lethal in another developmental context.   
 
 
Here, using transgenic rescue, I confirm that the 18-5 mutation is an allele of GEFmeso.  
I then explore the organization of GTPase networks in microdomains of the developing 
wing.  Finally, I examine interactions between GEFmeso and GTPase signaling 
components in wing microdomains.  I conclude that GTPase networks differ between 
microdomains of the wing epithelium.  This is the first study to my knowledge 
documenting and comparing GTPase signaling networks within a tissue in vivo. 
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CHAPTER TWO: METHODS 
 
Drosophila Stocks 
 
The Drosophila 18-5 mutant used in this study is described in Bayer et al, 2003.  All 
mutants were obtained from the Bloomington Drosophila Stock Center at Indiana 
University (Bloomington, IN).  All RNAi lines were either obtained from the Transgenic 
RNAi Project (TRiP) at Harvard Medical School or from the Vienna Drosophila RNAi 
Center (Dietzel et al, 2007; Ni et al, 2008).  Stocks were maintained either at 18oC or   
25oC on standard cornmeal/sugar/yeast media. 
 
Lethal Phase Analysis of 18-5 Mutant Homozygotes 
 
Embryonic lethality was determined by collecting 0- to 2-hr embryos from 18-
5/CyO,P[Dfd-EYFP} stocks.  Animals were aged for 13 hours and homozygotes selected 
based on absence of fluorescence.  Animals were monitored beginning at 24 hours after 
egg laying up to 72 hours after egg laying and dead embryos were counted.  Embryonic 
lethality was calculated as (number of dead mutant embryos/total number of mutant 
embryos) x 100.  The experiment was repeated twice for a total of 259 embryos scored. 
 
 
Larval lethality was determined by collecting non-fluorescing first instar animals from 
18-5/CyO,P{Dfd-EYFP} stocks.  Larvae were allowed to develop at 25oC at a density of 
50 animals per vial and were removed from vials as they pupariated.  Larval lethality was 
calculated as (number of mutant larvae-number of pupae)/number of mutant larvae x 100. 
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The experiment had three separate collection replicates for a total of 48 vials and 2,400 
larvae. 
 
 
To calculate pupal lethality, larvae from the larval lethal phase analysis were allowed to 
develop to pupariation and adult eclosers were counted.  Pupal lethality was calculated as 
(number of pupae-number of adult eclosers)/number of pupae x 100.  The experiment had 
three replicates for a total of 1,366 pupae.  For the stage of pupal lethality analysis, a 
random sample of 1,284 animals were chosen and observed for stage of arrested 
development. 
 
Construction of the hs-GEFmeso Transgenic Construct 
 
Full length GEFmeso was amplified from a cDNA (LP15490) (DGRC, EST collection) 
using primer pair (GEFmeso short reverse and GEFmeso long fwd2) listed in Table 1 and 
JumpStart Taq (Sigma, catalogue no. D4184).  
 
Table 1 Primers Used to Clone GEFmeso and Test GEFmeso Transgenes 
 
Primer Name Primer Sequence (5’-3’) 
GEFmeso Short Reverse ACTAGTTCTAGAGGCTCGTCTGTGCATCACTA 
GEFmeso Long Forward 2 AGATCTGCGGCCGCGGGCGAAAACTAACCCTACC 
GEFmeso.L.RT.F TCACTGTTCTGGGAGAGTTGC 
GEFmeso.L.RT.R CCAGCTGSTAGACCAGCTCCT 
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 PCR parameters were 94oC for 3 min and 30 cycles of (1 min 94oC, 1 min 55C, 1 min 
72oC).  The amplification remained at 20oC until it was stored at 4oC   Amplicons were 
visualized on a 0.8% low EEO agarose gel in 1xTAE buffer and PCR purified using a 
Quaquick PCR purification Kit (Qiagen Catalogue no. 28104).  Amplicons were cloned 
into the vector pCaSpeR-hs (Thummel and Pirrotta, 1992) following digestion with the 
restriction enzymes XbaI/NotI and separated on an 0.8% SeaPlaque GTG agarose gel in 
1xTAE buffer.  Products were gel purified as described above using a Qiaquick Gel 
Extraction Kit 9Qiagen, Catalogue No. 28704)  and ligated using a Rapid DNA ligation 
kit  (Roche, Catalogue no. 11635379001).  The ligation mixture was transformed into 
Max efficiency DH5α cells (Invitrogen) according to the manufacturer’s specifications 
with one exception.  50µl cells were mixed with the ligation mixture instead of 100µl 
cells.  The Transgene was injected into w[1118] embryos and established as stably 
transformed lines (11 lines total).  Genetic tests chromosome balancers were used to 
determine which chromosome the transgene inserted in.  An insertion on chromosome 
three, line 40A3 was used for the rescue experiments.  Activity of the transgene was 
verified by induction at 37oC in larvae for 60 minutes with no recovery time, and 
GEFmeso expression was measured RT-PCR and comparison to GEFmeso expression in 
non-induced transgenic animals.  The primer pair (GEFmeso.L.RT.F/GEFmeso.L.RT.R) 
used for RT-PCR is listed in Table 1. 
 
Genetic Analysis of GTPase Interactions in the Wing 
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To test for the requirement of various GTPases during wing vein formation, ten virgin 
females carrying the transgene(s) Bx>Gal4 driver or Bx>Gal4; UAS>Dcr2 were mated to 
five males carrying a RNAi responder construct.  Cultures were incubated at 18 oC, 25oC, 
ot 29 oC, depending on the strength of the phenotypes observed.  For 25 oC cultures, 
animals were allowed to lay eggs for five days in vials, and were then turned over onto 
fresh food for a further five days.  Progeny were collected for 19 days; beginning the day 
the parents were added to the vial.  All 18oC and 29oC matings were incubated at 25oC 
for three days, then the parents were removed and the vials were moved to 18oC and 29oC 
respectively.  Progeny were collected for 16 days for 29oC experiments and 38 days for 
18oC experiments; beginning the day the parents were added to the vial.  Animals were 
collected, and stored in fly preservative (3:1 70% ethanol: glycerol).  Wings were 
dissected from the animals, washed twice in 100% glycerol and mounted in 100% 
glycerol.  Preparations were heated to 50-55 oC for several hours, scored and 
photographed using an Olympus BX-FLA microsocope and Axiovision software.  
Animals carrying multiple transgenic constructs for co-expression analysis were 
constructed using appropriate balancers to combine two constructs within the same 
genotype. These animals were mated to Bx>Gal4 virgins and treated as described above.  
Progeny were collected and mounted as described above. 
 
 
To investigate the effect of over-expression of wild type GEFmeso in the wing, we made 
a UAS>GEFmeso transgenic construct.  UAS>GEFmeso was made as described for the 
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hs-GEFmeso construct except the cDNA was ligated into the pUAST vector (Brande and 
Perrimon, 1993).   
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CHAPTER THREE: RESULTS 
 
We have previously reported the isolation of a mutant allele, designated 18-5, which 
interacts genetically with the Rho1 and Sb-sbd loci to control leg and wing imaginal disc 
morphogenesis (Bayer et al, 2003).  Three lines of evidence suggest that 18-5 is an allele 
of GEFmeso (CG30115; Blanke and Jackle).  First, genetic mapping experiments place 
lethality associated with the 18-5 mutation in a region containing GEFmeso (Fox, 2006).  
Second, rare 18-5 homozygous adults have wing defects similar to those observed 
following RNAi knockdown of GEFmeso in the wing (Fox, 2006; Blanke and Jackle, 
2006).  Third, sequencing of the GEFmeso locus in 18-5 homozygous animals reveals a 
deletion that impairs GEFmeso function (Morgan, Smallwood, and von Kalm, 
unpublished). 
 
 
In order to investigate the relationship between the 18-5 allele and GEFmeso, I performed 
a functional rescue with a GEFmeso transgene.  Prior to conducting rescue experiments I 
conducted a lethal phase analysis of 18-5 mutant homozygotes to better understand the 
developmental requirements for the 18-5 gene product and to establish an appropriate 
period for transgene expression.  
 
Lethal Phase Analysis of the 18-5 allele 
 
Embryonic, larval, and pupal survival data for 18-5 homozygotes are shown in Table 2.  
Approximately one-quarter of 18-5 homozygous embryos fail to hatch, and slightly more 
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than one-half of homozygous larvae fail to survive to pupariation.  Of animals that enter 
metamorphosis, only 2% eclose as adults successfully, indicating a major requirement for 
the 18-5 gene product during adult development.   
 
Table 2 18-5 Embryonic, Larval and Pupal Lethal Phase Analysis for 18-5 
Homozygotes 
 
 
Embryonic viability was calculated as the percentage of homozygous embryos that failed 
to hatch as larvae (see methods for details).  Larval viability was calculated as the 
percentage of larvae that failed to survive to pupariation.  Pupal viability was calculated 
as the percentage of adults that eclosed of animals that were able to form pupal cases. 
Values shown are percentages +/- SEM from two (embryonic) or three (larval and pupal) 
replicates. 
 
To further characterize the requirement for the 18-5 gene product during adult 
development I determined the stage of pupal lethality in mutant animals (Table 3).  As 
shown in Table 3, lethality occurs throughout the prepupal and pupal stages, but is 
focused in the early and later stages of adult development.  Interestingly, almost a quarter 
of animals die as late pupae during eclosion.  Of animals that survived to initiate 
eclosion, nearly all animals showed a partial eclosion phenotype (Tables 3, 4).  
Dissection of late stage pupa from their pupal cases revealed that 76.4% (n=127) exhibit 
a wing defect where at least one wing everts in an anterior rather than posterior direction 
(Figure 4.B,D).  Some animals that are able to eclose lose their wings during the eclosion 
process.  Visual examination of dissected late stage pupae also revealed a low frequency 
of leg extension defects (data not shown).   
Genotype Embryonic  Lethality  Larval  Lethality Pupal  Lethality  
18-5/18-5 26.6  +/-  3.0 57.4 +/- 1.3 98.0 +/- 0.3 
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Table 3 Lethal Phase Analysis of the Pupal Phase in 18-5 Homozygotes 
 
Phase % of N 
Died as Elongated/Prepupae 10.2 
Died as Prepupae and Young Pupae 27.6 
Died as Mid Pupae (unpigmented) 25.7 
Died as Late Pupae (pigmented) 10.4 
Died during eclosion 24.2 
Animals Eclosed  1.9 
 
Percentages represent animals that died during pupal development or eclosed as adults 
(Animals eclosed). N=1366.  Numbers calculated from three replicates. 
 
Table 4 Analyses of 18-5 Homozygotes that Die at Eclosion 
 
Eclosion Status % of N 
Partially eclosed 92.4 
Eclosed  7.6 
 
Percentages represent pupae that initiated eclosion and either eclosed or failed to 
complete eclosion (partially eclosed).  N=357.  Numbers calculated from three replicates. 
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A) OreR pupa. B) 18-5/18-5 pupa. C) Dissected OreR pupa. D) Dissected 18-5/18-5 
pupa with an anteriorally everted wing 
 
Figure 4 GEFmeso transgene rescues the anteriorally everted wing phenotype 
associated with 18-5 
 
Functional Rescue of 18-5 Mutant Homozygotes with a Wild-Type GEFmeso Transgene 
 
Genetic mapping experiments indicate that lethality associated with the 18-5 mutation 
maps to a short interval on chromosome two that includes the guanine nucleotide 
exchange factor, GEFmeso (Fox and Smallwood, unpublished data).  Furthermore, 18-5 
homozygotes have ectopic wing veins that mirror phenotypes observed in animals where 
GEFmeso RNAi is expressed in the wing (Blanke and Jackle, 2006).  To confirm if 18-5 
is a mutation in GEFmeso, I asked if a heat-inducible GEFmeso transgene could rescue 
mutant phenotypes associated with 18-5 homozygotes.  I generated transgenic animals 
with a wildtype copy of GEFmeso under control of a heat shock-inducible promoter, 
induced expression in an 18-5 homozygous genetic background and assessed changes in 
viability, leg malformation and wing eversion orientation.  GEFmeso is expressed 
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throughout Drosophila development, however, expression peaks during late 
embryogenesis and again beginning at the onset of morphogenesis, continuing for two 
days afterward (Blanke and Jackle, 2006; Graveley et al, 2011).  Strong expression of 
GEFmeso during early adult development is consistent with the observation that a 
majority of animals show an anteriorally-everted wing likely due to morphogenetic 
defects during the first 12 hours of the pupal period.  The expression data and lethal 
phase analysis indicate that there is a heightened requirement for GEFmeso expression 
during the early pupal stages.  Therefore, I induced the GEFmeso transgene twice during 
this phase of development (37oC, 60 min each).  The first induction occurred in late 
larvae within a few hours of pupariation.  The second induction of GEFmeso expression 
occurred 12 hours later.  This regimen increased adult viability 15-fold compared to 
untreated animals lacking the GEFmeso transgene (Table 5).  In contrast, a single 
induction of GEFmeso delivered only to late larvae, increased adult viability 10-fold 
(Table 5) compared to untreated animals lacking a transgene.  Heat treatment alone in the 
absence of a transgene did not rescue 18-5 lethality and reduced viability compared to 
untreated controls (Table 5).   
 
 
Expression of the GEFmeso transgene also suppressed the frequency of the wing eversion 
and leg malformation phenotypes of 18-5 homozygotes.  Expression of the GEFmeso 
transgene in late larvae and then twelve hours later reduced the frequency of the anterior 
everted wing phenotype from 75% to 5.5% (Table 6).  Weaker rescue of the everted wing 
phenotype was observed if the induction of the GEFmeso transgene was limited to late 
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larvae.  In addition, expression of the GEFmeso transgene rescued leg malformation 
associated with homozygous 18-5 mutant animals from 77% to 28% (Table 7). 
Collectively, these data indicate the 18-5 mutation is an allele of GEFmeso.  Henceforth, 
I will refer to 18-5 as GEFmeso. 
 
Table 5 A GEFmeso Transgene Rescues Lethality Associated with 18-5 Mutant 
Homozygotes 
 
Genotype Treatment % Viability N 
18-5/18-5 ; +/+ Untreated 1.9+/-0.3 1,366 
18-5/18-5 ; t/+ Untreated 4.6 +/- 1.8  554 
18-5/18-5 ; +/+ Late larvae + 
12hrs (PP) 
0.0 +/- 0.0  76 
18-5/18-5 ; t/+ Late larvae 
+12hrs (PP) 
29.4 +/- 6.6  234 
18-5/18-5 ; t/+ Late larvae  20.5+/-1.9  156 
 
Animals with and without transgene (indicated by t) were either treated at 37oC for 60 
minutes for the indicated protocol or left untreated and survival to adulthood was 
determined. 
 
Table 6 A GEFmeso Transgene Rescues the Anterior Everted Wing Phenotype 
Associated with 18-5 Mutant Homozygotes 
 
Genotype Treatment Anterior Everted 
Wing Phenotype (%) 
N 
18-5/18-5 ; t/+ Untreated 73.3 206 
18-5/18-5  Untreated 76.4 127 
18-5/18-5 ; t/+ Late larvae + 
12hrs 
 7.5 108 
18-5/18-5 ; t/+ Late Larvae   38.2 64 
 
Animals with and without transgene (indicated by t) were either treated at 37oC for 60 
minutes at the indicated times or left untreated and the frequency of animals with at least 
one anteriorally-everted wing was determined 
 21 
 
Table 7 A GEFmeso Transgene Rescues Leg Malformation Associated with 18-5 
Mutant Homozygotes 
 
 WT Mild Severe 
Control 23.0% (26) 15.3% (26) 61.5% (26) 
1X as Late 
Larvae 
50.0% (32) 6.2% (32) 43.7% (32) 
Late Larvae 
+12hr 
72.2% (72) 9.7% (72) 18.0% (72) 
 
Animals were treated at 37oC for 60min at the indicated time points.  Control animals 
were not treated and maintained at 25oC.  The numbers shown indicate the percentage of 
animals with malformed legs, with the total number of animals of the indicated genotype 
shown in parentheses. Experiments represent three replicates. 
 
The Requirements for Rho GTPases During Wing Vein Formation Vary in Different 
Microenvironments of the Wing 
 
GTPases are master regulators of most cell behaviors and a variety of tools have been 
developed for in vivo and in vitro investigations of their functions.  Drosophila geneticists 
utilize a range of tools (mutants, RNAi, over-expression, dominant negative and 
constitutively active constructs) to investigate the roles of GTPases in various aspects of 
development.  Tools allowing gene expression manipulation and cell imaging techniques 
provide evidence that cell processes coordinating tissue development (cell polarization, 
morphodynamics and migration) are GTPase-dependent.  More recently, insights brought 
to the field by biochemical methods such as fluorescent tagging, imaging, and binding 
assays have shown GTPases may function antagonistically, synergistically or 
independent of one another to regulate cell behaviors.  These biochemical approaches 
demonstrate that GTPase signaling programs are variable at the cellular level (Pertz, 
2010).  However, the question of whether intercellular GTPase signaling networks 
variation occurs within a single tissue is still unknown.  
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In the adult, a wild type wing has six longitudinal veins (L1-L6) separated by intervein 
tissue.  Positioned along the proximal-distal axis are the anterior and posterior cross veins 
(ACV and PCV). 
 
Figure 5 Topography of the Adult Wing 
 
In order to investigate intercellular variability of GTPase networks, I have focused on a 
single developmental context, the Drosophila wing and specifically the formation of the 
two predominate tissues, vein and intervein (Figure 5).  Since GTPase signals are 
intricately modulated, I opted to use an RNAi loss-of-function approach to investigate 
relationships between GTPases during wing vein development.  I also used over-
expression constructs, but only when there was an RNAi phenotype.  Gain-of-function 
constitutively active and dominant negative mutants and transgenic constructs were 
excluded from the analysis because they have the potential to alter multiple GTPase 
signaling pathways, potentially confounding interpretation.  To focus this investigation, I 
limited the analysis to regions of the wing requiring GEFmeso function.  
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GEFmeso is Required for Wing Vein Morphogenesis 
 
GEFmeso is expressed ubiquitously in the wing imaginal disc in third instar larvae 
(Blanke and Jackle, 2006).  Furthermore, disruption of expression or proper function 
results in two distinct wing phenotypes.  First, GEFmeso18-5 interacts genetically with 
members of the Rho1 signaling pathway resulting in a ‘crumpled’ malformed wing 
phenotype (Bayer et al, 2003).  Second, perturbing GEFmeso function or expression 
alters the wing vein pattern (Blanke and Jackle, 2006).   
 
 
Animals homozygous for GEFmeso18-5 have ectopic anterior cross veins and ectopic vein 
material between longitudinal veins (L) two and three (Iketani, Fox and von Kalm, 
unpublished observations).  RNAi against GEFmeso targeted to the wing using the Bx-
Gal4 driver also results in ectopic cross veins adjacent to the anterior cross vein and/or 
between L2 and L3 (Figure 3).  These results indicate that GEFmeso is required to 
suppress vein formation in the intervein region proximal and distal to the anterior cross 
vein.  Ectopic veins observed in 18-5 homozygotes and GEFmeso RNAi animals 
indicates GEFmeso suppresses vein formation and in the intervein region between L2 and 
L3.  Consistent with these observations, over-expression of GEFmeso throughout the 
entire wing using the Bx-Gal4 driver results in a loss of anterior cross vein phenotype.  
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 Over-expression of GEFmeso also results in a loss of posterior cross vein material and 
the appearance of ectopic vein material surrounding the distal regions of L3 and L4.  In 
contrast, GEFmeso RNAi expressed in the wing or GEFmeso18-5 mutants exhibit neither 
phenotype.  There are two interpretations of these observations.  First, GEFmeso is able 
to suppress posterior cross vein formation and maintain intervein identity in the distal 
regions of L3 and L4, but may not be required in these microdomains.  Alternatively, 
these phenotypes could be an artifact caused by over-expression of a protein that is not 
endogenous in these regions of the wing.  
 
Requirements for GTPase signaling in Microdomains of the Wing 
 
To investigate variation in networks requiring GEFmeso, I first identified GTPases 
required for wing vein development using an RNAi approach and assessed the impact on 
various microdomains in the wing (cross veins, longitudinal veins and intervein regions).  
I tested twelve genes by expressing RNAi transgenes in the wing and examined twelve 
microdomains (ACV, PCV, L2-L5 and intervein regions L1/L2, L2/L3, L3/L4, posterior 
to L5).  I used the Beadex-Gal4 (Bx-Gal4) driver to express transgenes in the wing.  This 
driver is located on the X chromosome and therefore the transgene has stronger 
expression in males than heterozygous females.  After expressing the RNAi transgenes, I 
catalogued vein abnormalities as either ectopic tissue or loss of wild type tissue for each 
microdomain.  The results from the RNAi studies revealed that the genes fit into one of 
three categories: 1) the gene is not required for vein development, 2) the gene is required 
for vein morphogenesis in a limited number of microdomains and is dispensable in 
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others, or 3) the gene is required globally for vein development (Table 8).  In the 
following sections, I discuss each gene tested individually.  I begin by discussing genes 
that have global effects on wing vein development and then discuss genes with more 
limited phenotypes.  
 
Table 8 Genes Tested in this Study and the Number of Microdomains Affected 
 
Gene Number of Microdomains Affected 
GEFmeso 3 
Ras85D 6 
Egfr 6 
Rho1 3 
Mtl 3 
Ras64B 2 
RhoGAPp190 2 
RhoGEF2 3 
Rac1 2 
Rala 3 
Cdc42 2 
Roughened 0 
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A) w1118 control, B) Bx-G4>UAS-Egfr.RNAi 18oC, C) Bx-G4>UAS-Ras85D.RNAi 18oC 
 
Figure 6 Egfr and Ras85D are Global Regulators of Wing Vein Formation 
 
Ras85D and Egfr are Global Regulators of Wing Vein Formation 
 
Of the twelve genes tested, two signaling components (Egfr and Ras85D) behave as 
global regulators throughout the wing epithelium (Figure 6).  The criterion to be 
classified, as a global regulator is to disrupt proper vein formation in at least half of the 
microdomains examined after RNAi expression.  The role of Egfr as a global regulator of 
of wing vein development has been well established and was confirmed in this study 
(Blair, 2007; Appendix). In addition, this study revealed a second and previously 
unreported global regulator, Ras85D, which is required for vein formation in many 
regions of the wing (Figure 6C; Table 9).  
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All animals are Bx-G4>UAS-Ras85D.RNAi at 25oC.  A) Anterior cross vein, B) 
Posterior cross vein, C) Longitudinal vein four, and D) Longitudinal vein five 
 
Figure 7 Ras85D RNAi Wing Phenotypes 
 
Animals expressing Ras85D RNAi in the wing had several phenotypes.  First, vein 
material was lost from the distal and/or the center portions of the vein.  Second, while L2 
was typically unaffected, L5 was severely affected with loss of all material except the 
proximal section.  Third, the anterior and posterior cross veins were either partially or 
completely absent (Table 9 and Figure 7 A, B).  Collectively, these results indicate that 
Ras85D is required for formation of L3, L4, and L5, and both cross veins.  If Ras85D is a 
global regulator of wing vein formation we predict that over-expression will lead to 
ectopic vein material throughout the wing.  As expected, over-expression of Ras85D in 
the wing results in ectopic wing vein material in L2-L5 and the intervein region between 
L4 and L5 (Appendix A).  
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Table 9 Microenvironments that Require Ras85D 
 
                                           Wing Phenotype (%) 
Genotype Sex Micro-
envronment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-Ras85D.RNAi M ACV 100 - 50 25 
Bx-G4>UAS-Ras85D.RNAi F ACV 97.4 - 39 25 
Bx-G4>UAS-Ras85D.RNAi M ACV 96.7 - 61 18 
Bx-G4>UAS-Ras85D.RNAi F ACV 62.5 - 56 18 
Bx-G4>UAS-Ras85D.RNAi M PCV 97.8 - 50 25 
Bx-G4 >UAS-Ras85D.RNAi F PCV 97.4 - 39 25 
Bx-G4 >UAS-Ras85D.RNAi M PCV 96.7 - 61 18 
Bx-G4>UAS-Ras85D.RNAi F PCV 82.1 - 56 18 
Bx-G4>UAS-Ras85D.RNAi M L4 100 - 50 25 
Bx-G4>UAS-Ras85D.RNAi F L4 89.7 - 39 25 
Bx-G4>UAS-Ras85D.RNAi M L4 21.3 - 61 18 
Bx-G4>UAS-Ras85D.RNAi F L4 10.7 - 56 18 
Bx-G4>UAS-Ras85D.RNAi M L5 100 - 50 25 
Bx-G4>UAS-Ras85D.RNAi F L5 97.4 - 39 25 
Bx-G4>UAS-Ras85D.RNAi M L5 1.6 - 59 18 
Bx-G4>UAS-Ras85D.RNAi F L5 23.2 - 59 18 
 
In contrast to Ras85D, wings expressing Egfr RNAi had a complex phenotype involving 
both loss of and ectopic vein material across the wing epithelium.  For example, loss of 
both anterior and posterior cross veins and loss of vein material from L4 and L5 was 
observed, indicating a requirement for Egfr to promote vein formation in these regions.  
In addition, ectopic cross veins, and spots of vein material in the L2/L3 intervein region 
were observed (Figure 8C and Table 10).  In contrast to Egfr RNAi, Ras85D RNAi has a 
uniform loss of vein material phenotype across the entire wing epithelium  
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All animals are Bx-G4>UAS-Egfr.RNAi 18oC 
Loss of the anterior cross vein phenotype, B) Loss of the posterior cross vein phenotype, 
C) Arrowhead is pointing to ectopic material in the L2/L3 Intervein region, D) 
Arrowhead is pointing to a loss of longitudinal vein four phenotype and E) Arrowhead is 
pointing to an incomplete longitudinal vein five phenotype 
 
Figure 8 Microdomains that Require Egfr 
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Table 10 Microenvironments that Require Egfr 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Egfr.RNAi 
F ACV 100 - 47 25 
Bx-G4>UAS-
Egfr.RNAi 
M ACV NS NS NS 25 
Bx-G4>UAS-
Egfr.RNAi 
F ACV 100 - 47 18 
Bx-G4>UAS-
Egfr.RNAi 
M ACV 100 - 22 18 
Bx-G4>UAS-
Egfr.RNAi 
F PCV 97.3 - 38 25 
Bx-G4>UAS-
Egfr.RNAi 
M PCV NS NS NS 25 
Bx-G4>UAS-
Egfr.RNAi 
M PCV 45.5 - 22 18 
Bx-G4>UAS-
Egfr.RNAi 
F PCV 82.9 - 47 18 
Bx-G4>UAS-
Egfr.RNAi 
F L2/L3 - 29.7 47 18 
Bx-G4>UAS-
Egfr.RNAi 
M L2/L3 0 0 22 18 
Bx-G4>UAS-
Egfr.RNAi 
F L4 86.8 - 38 25 
Bx-G4>UAS-
Egfr.RNAi 
M L4 NS NS NS 25 
Bx-G4>UAS-
Egfr.RNAi 
M L4 100 - 22 18 
Bx-G4>UAS-
Egfr.RNAi 
F L4 17.0 - 47 18 
Bx-G4>UAS-
Egfr.RNAi 
F L5 92.1 - 38 25 
Bx-G4>UAS-
Egfr.RNAi 
M L5 NS NS NS 25 
Bx-G4>UAS-
Egfr.RNAi 
M L5 100 - 22 18 
Bx-G4>UAS-
Egfr.RNAi 
F L5 36.1 - 47 18 
 
NS indicates wings were too malformed to be scored. 
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Rho1 is Required for Anterior Cross Vein Formation and Suppresses Formation of the 
Posterior Cross Vein and Vein material in the L2/L3 Intervein Region 
 
The role of Rho1 in wing vein development has not been well established and our results 
indicate a more limited role in wing vein formation.  Like Egfr, Rho1 can promote or 
suppress vein development in different regions of the wing. 
 
Table 11 Microenvironments that Require Rho1 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Rho1. RNAi 
M ACV 41.2 - 38 25 
Bx-G4>UAS-
Rho1. RNAi 
F ACV 53.7 - 95 25 
Bx-G4>UAS-
Rho1. RNAi 
M ACV 39.1 - 46 18 
Bx-G4>UAS-
Rho1. RNAi 
F ACV 54.3 - 57 18 
Bx-G4>UAS-
Rho1.RNAi 
M PCV 20.6 50.0 38 25 
Bx-G4>UAS-
Rho1.RNAi 
F PCV 13.7 66.3 95 25 
Bx-G4>UAS-
Rho1.RNAi 
M PCV 10.8 26.2 46 18 
Bx-G4>UAS-
Rho1.RNAi 
F PCV 8.7 28.0 57 18 
Bx-G4>UAS-
Rho1.RNAi 
M L2/L3 - 14.7 38 25 
Bx-G4>UAS-
Rho1.RNAi 
F L2/L3 - 13.7 95 25 
Bx-G4>UAS-
Rho1.RNAi 
M L2/L3 - 21.7 46 18 
Bx-G4>UAS-
Rho1.RNAi 
F L2/L3 - 10.5 57 18 
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At 25oC, Rho1 RNAi resulted in an incomplete loss of the anterior cross vein as well as a 
blurred boundary between intervein and vein material.  At 18 oC, the phenotype was 
similar with a faint to complete or incomplete loss of the ACV.  We conclude that Rho1 
is required for anterior cross vein formation.  In contrast, Rho1 has a complex phenotype 
in the PCV with some animals exhibiting PCV loss and others with ectopic vein material 
(Table 11; Figure 9 A, B). In addition, reduced Rho1 expression resulted in ectopic vein 
spots along the proximal-distal axis in the L2/L3 intervein region (Figure 9 C and Table 
11). 
 
 
A) Anterior cross vein (Bx-G4>UAS-Rho1.RNAi 25oC), B) Posterior cross vein (Bx-
G4>UAS-Rho1.RNAi 25oC) and C) Intervein L2/L3 (Bx-G4>UAS-Rho1.RNAi 18oC), 
 
Figure 9 Microdomains that Require Rho1 
 
GEFmeso and Mtl Interact in the Anterior Cross Vein and longitudinal Vein Five 
 
Mtl is one of three Rac orthologs found in Drosophila (Lindquist, 2006; Van Aelst and 
Symons, 2002; Hakeda-Suzuki et al, 2002).  Reduced Mtl expression caused mild 
incomplete loss of the PCV indicating a requirement for vein formation in this region in 
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the wing (Figure 10 A and Table 12).  In contrast, RNAi against Mtl resulted in ectopic 
vein material around L4 and L5 (Figure 10 B, C and Table 12).  RNAi against Mtl 
affected male wings but did not exhibit phenotypes in females, indicating a stronger 
knockdown is needed to affect vein pattern.  
 
 
 
A) An incomplete PCV phenotype (Bx-G4>UAS-Mtl.RNAi 25oC), B) Ectopic vein 
material extending from L5 (Bx-G4>UAS-Mtl.RNAi 29oC), and C) Short, ectopic 
vein material in the intervein region posterior to L5 (Bx-G4>UAS-Mtl.RNAi 29oC) 
 
Figure 10 Microdomains that Require Mtl 
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Table 12 Microenvironments that Require Mtl 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Mtl.RNAi 
M PCV 18.3 - 60 25 
Bx-G4>UAS-
Mtl.RNAi 
M PCV 17.5 - 57 29 
Bx-G4>UAS-
Mtl.RNAi 
M L4 - 38.5 57 29 
Bx-G4>UAS-
Mtl.RNAi 
M L5 - 26.6 60 25 
Bx-G4>UAS-
Mtl.RNAi 
M L5 - 59.6 57 29 
 
Rac1 is Required to Define the Boundaries of Longitudinal Veins Four and Five 
 
Rac1 is required for morphogenesis, however a role in wing vein development has not 
been documented (Eaton et al, 1995).  RNAi Rac1 caused ectopic veins to form around 
L4 and L5 (Table 15 and Figure 12).  At a higher temperature (stronger RNAi 
expression) the L5 phenotype became variable with both loss and gain of material 
observed (Table 15).  Again, only males had phenotypes after Rac1 RNAi expression 
indicating a high level of RNAi expression is needed to produce a phenotype. 
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Table 13 Microenvironments that Require Rac1 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Rac1.RNAi 
M L4 0 40 45 29 
Bx-G4>UAS-
Rac1.RNAi 
M L5 0 14.4 47 25 
Bx-G4>UAS-
Rac1.RNAi 
M L5 15.7 53.3 45 29 
 
 
 
Both wings are Bx-G4>UAS-Rac1 RNAi at 25oC.  A) Ectopic extension from L4 is 
indicated by the arrowhead and B) Ectopic extension from L5 is indicated by the 
arrowhead 
 
Figure 11 Microenvironments that Require Rac1 
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Ras64B is Required to Refine The Distal Ends of Longitudinal Veins Four and Five 
 
The role of Ras64B on wing vein formation is unknown, but previous work indicates 
Ras64B may specify vein formation.  Expression of activated Ras64B in the wing results 
in ectopic veins in intervein region L2/L3, ectopic extensions from the PCV and a 
thickened L3 (de Celis, 1997).  RNAi against Ras64B results in ectopic vein extensions 
from the distal end of L4 and L5 (Table 13).  No other defects were observed, raising the 
possibility that the previously reported observations involving expression of an activated 
Ras64B in the wing may not play a normal role there.  Only males had phenotypes, which 
indicates that a strong knockdown is required to have an effect on the wing vein pattern. 
 
Table 14 Microenvironments that Require Ras64B and RhoGAPp190 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Ras64B.RNAi 
M L4 - 33.8 59 29 
Bx-G4>UAS-
Ras64B.RNAi 
M L5 - 52.5% 59 29 
Bx-G4, UAS-
Dcr2>UAS-
RhoGAPp190. 
RNAi 
M ACV 62.2 - 56 25 
 
RhoGAPp190 is Active in the Anterior Cross Vein 
 
Currently, the role of RhoGAPp190 during wing vein formation is unknown.  I expressed 
RNAi against RhoGAPp190 in the wing to determine if this GTPase regulator is required 
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for vein patterning. UAS-Dicer2 was included and required to amplify the RNAi 
response to a biologically significant level.  Only one region of the wing was affected. 
RNAi against RhoGAPp190 caused the ACV to become faint, albeit still visible (Table 
13).  In contrast, over-expression of RhGAPp190 leads to a widespread ectopic vien 
phenotype (C. Bayer, unpublished data) suggesting that RhoGAPp190 may act 
redundantly in many regions of the wing. 
RhoGEF2 Suppresses Vein Formation in the Intervein Regions, the Posterior Cross Vein 
and Longitudinal Vein Four 
Linking role for RhoGEF2 in wing vein development has not been previously reported.  
RNAi against RhoGEF2 resulted in ectopic vein material around the PCV, L4, and in the 
L2/L3 intervein region (Figure 11 and Table 14). 
 
 
Both images are from Bx-G4>UAS-Dcr2; UAS-RhoGEF2.RNAi animals at 25oC 
A) Ectopic vein material in the L2/L3 Intervein intervein region and B) Ectopic extension 
from the PCV 
 
Figure 12 Microdomains Requiring RhoGEF2 
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Table 15 Microenvironments that Require RhoGEF2 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4;UAS-
Dcr2>UAS-Rho 
GEF2.RNAi 
M PCV 0 19.6 56 25 
Bx-G4;UAS-
Dcr2>UAS-Rho 
GEF2.RNAi 
F PCV 0 24.6 57 25 
Bx-G4;UAS-
Dcr2>UAS-
RhoGEF2. 
RNAi 
M L2/L3 0 28.5 56 25 
Bx-G4;UAS-
Dcr2>UAS-
RhoGEF2. 
RNAi 
M L4 0 23.2 56 25 
 
 
Rala is Required to Form the Anterior and Posterior Cross Veins 
 
The effect of Rala RNAi was limited to the ACV and PCV where a strong loss of vein 
phenotype was observed (Figure 13 and Table 16). 
 
 
A) Faint loss of ACV phenotype (Bx-G4>UAS-Rala.RNAi at 25oC) and B) 
Incomplete loss of PCV phenotype (Bx-G4>UAS-Rala.RNAi at 18oC) 
 
Figure 13 Microdomains Requiring Rala 
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Table 16 Microenvironments that Require Rala 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
Bx-G4>UAS-
Rala.RNAi 
F ACV 94.2 - 87 25 
Bx-G4>UAS-
Rala.RNAi 
M ACV 89.4 - 19 25 
Bx-G4>UAS-
Rala.RNAi 
M ACV 46.8 - 47 18 
Bx-G4>UAS-
Rala.RNAi 
M PCV 94.7 - 19 25 
Bx-G4>UAS-
Rala.RNAi 
F PCV 96.5 - 15 25 
Bx-G4>UAS-
Rala.RNAi 
M PCV 91.4 - 59 18 
Bx-G4>UAS-
Rala.RNAi 
F PCV 28.8 - 47 18 
 
Interactions Between GEFmeso and Other GTPase Signaling Components in the Wing 
 
The single gene analysis indicated specific roles for GTPase signaling components in the 
wing.  I next asked if genetic interactions between gene pairs are observed in different 
regions of the wing.  To narrow the focus, I examined interactions between GEFmeso and 
other GTPase signaling genes.  These experiments were performed by simultaneous 
RNAi against the GTPase signaling gene and GEFmeso or by RNAi in combination with 
heterozygosity for the GEFmeso18-5 mutation (i.e. 18-5/+). 
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Reduced GEFmeso Expression Suppresses the Rala RNAi Phenotype in the Anterior and 
Posterior Cross Veins 
 
Blake and Jackle (2006) showed in vitro that GEFmeso binds to GTP-bound Rala in a 
region distinct from the DHPH domain.  I have shown that Rala and GEFmeso are 
required for the ACV development, albeit with opposite activities (loss of ACV with 
RNAi Rala and ectopic ACV with RNAi GEFmeso).  In addition, over-expression of 
GEFmeso (but not RNAi knockdown which has no phenotype) leads to loss of the PCV, 
a phenotype also seen with RNAi Rala.  To investigate in vivo interactions between 
GEFmeso and Rala I tested for interactions between GEFmeso and Rala in the anterior 
and posterior cross veins by co-expressing Rala RNAi with GEFmeso RNAi or in a 
GEFmeso18-5 heterozygous background.  In both instances, the penetrance of the Rala 
RNAi phenotype was suppressed.  For example, in the ACV 94% of animals show a loss 
of ACV phenotype following Rala RNAi, whereas only 5% of animals have this 
phenotype in a Rala RNAi GEFmeso RNAi animals.  Suppression of the Rala phenotype 
was consistently stronger in the ACV than the PCV (Tables 17 and 18).  In addition, the 
amount of ectopic vein material in the ACV of double RNAi animals increased which is a 
phenotype associated with RNAi GEFmeso but not RNAi Rala.  These results indicate an 
antagonistic relationship between GEFmeso and Rala.  A genetic interaction is not 
unexpected since in vitro experiments show physical interactions between GEFmeso and 
Rala (Blanke and Jackle, 2006).  
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Table 17 Interactions Between Rala and GEFmeso in the Anterior Cross Vein 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
18-5/+ F ACV 1.7 - 58 25 
Bx-G4>UAS-
GEFmeso. 
RNAi 
F ACV - 4.6 107 25 
Bx-G4>UAS-
Rala.RNAi 
F ACV 94.2 - 88 25 
Bx-G4>UAS-
Rala.RNAi;   
18-5/+ 
F ACV 49 - 53 25 
Bx-G4> UAS-
Rala.RNAi; 
UAS-GEFmeso. 
RNAi 
F ACV 5.5 11.1 36 25 
 
Table 18 Interactions between GEFmeso and Rala in the Posterior Cross Vein 
 
                           Wing Phenotype (%) 
Genotype Sex Micro-
environment 
Loss Ectopic n T (oC) 
18-5/+ F PCV 0 - 58 25 
Bx-G4>UAS-
GEFmeso. 
RNAi 
F PCV 0 - 107 25 
Bx-G4>UAS-
Rala.RNAi 
F PCV 96.5 - 88 25 
Bx-G4>UAS-
Rala.RNAi; 
18-5/+ 
F PCV 71.6 - 53 25 
Bx-G4> UAS-
Rala.RNAi; 
UAS-GEFmeso. 
RNAi 
F PCV 75 - 36 25 
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Reduced GEFmeso Expression Enhances the Rac1 Anterior Cross Vein Phenotype 
 
I also tested for interactions between GEFmeso and Rac1.  A small percentage (3%) of 
Rac1 RNAi animals have an anterior cross vein defect.  In contrast, GEFmeso18-5 and 
GEFmeso RNAi animals have ectopic ACV phenotypes.  Rac1 RNAi expressed in a 
GEFmeso18-5 heterozygous background enhanced the Rac1 loss of ACV phenotype 7-fold 
(Table 19).  A similar pattern, but weaker interaction occurred in the PCV (Table 19).  
Overall, the data indicate an interaction between Rac1 and GEFmeso in the ACV.  
 
Table 19 GEFmeso and Rac1 interact in the Anterior Cross Vein 
 
       Wing Phenotype (%) 
Genotype Sex ACV Loss PCV Loss N T 
(oC) 
18-5/+ M 0 0 60 25 
Bx-G4>UAS-
Rac1.RNAi 
M 3.1 14.7 95 25 
Bx-G4>UAS-
Rac1.RNAi;  
18-5/+ 
M 22.8 24.5 57 25 
 
There were several microdomains where either GEFmeso or Rac1 was required for vein 
development, but there was no genetic interaction in these microdomains.  For example, 
RNAi Rac1 results in ectopic tissue extending from L4, L5 and in the intervein region 
posterior to L5.  Simultaneously removing a copy of 18-5 did not affect these phenotypes 
(Table 20).  Thus the interaction between Rac1 and GEFmeso is context dependent and 
varies in different microdomains in the wing. 
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Table 20 Rac1 and GEFmeso Do Not Interact Genetically in Longitudinal Veins 
Four and Five or Posterior to Longitudinal Vein Five 
 
                           Ectopic Veins(%) 
Genotype Sex L4 L5 Posterior 
to L5 
n T (oC) 
18-5/+ M 0 0 0 60 25 
Bx-G4>UAS-
Rac1.RNAi 
M 9.5 13.4 29.8 95 25 
Bx-G4> UAS-
Rac1.RNAi;  
18-5/+ 
M 0 19.2 26.3 57 25 
 
Reduced GEFmeso Expression Enhances Mtl RNAi Phenotypes in the Anterior Cross 
Vein, the Posterior Cross Vein, and Longitudinal Vein Five 
 
I tested for interactions between GEFmeso and Mtl in vivo.  Mtl RNAi animals do not 
have an ACV phenotype, but do have a loss of PCV phenotype.  Expression of Mtl RNAi 
in a GEFmeso18-5 heterozygous mutant enhances the loss of cross vein phenotype in both 
veins (Table 21).  Mtl RNAi results in ectopic tissue surrounding longitudinal vein five.  
The two major phenotypes are extensions from longitudinal vein five or ectopic tissue 
directly posterior to L5 (compare Figures. 10.C and 12.B to observe differences in the 
phenotype).  Mtl RNAi results in 32% of animals with ectopic material in or around L5. 
In contrast, expression of Mtl RNAi in a GEFmeso18-5 heterozygous background 
increased the penetrance of this phenotype to 70% (Table 21).  Thus, Mtl and GEFmeso 
appear to interact genetically in the ACV, PCV in the region around L5. 
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Table 21 Mtl and GEFmeso Interact in the Posterior Cross Vein, Longitudinal Vein 
Five and in the Intervein Region Posterior to Longitudinal Vein Five 
 
  Loss of Veins (%) Ectopic Veins (%)  
Genotype Sex ACV PCV L5 Posterior 
to L5 
n T (oC) 
18-5/+ M 0 0 0 0 60 25 
Bx-G4> UAS-
Mtl.RNAi 
M 8.3 18.3 26.6 5.7 60 25 
Bx-G4> UAS-
Mtl.RNAi; 
18-5/+ 
M 20.3 37.2 14 56 59 25 
 
Reduced GEFmeso Expression Enhances the Ras85D RNAi Loss of Longitudinal Vein 
Phenotypes 
 
Since Ras85D is a global regulator of wing development, we tested for an interaction 
with GEFmeso.  RNAi Ras85D animals exhibited loss of ACV, PCV, L2, L3, L4, and L5 
vein material.  The strongest phenotypes were in the ACV, PCV and L5 (Appendix A).  
The weakest phenotype was in L2.  Reduced GEFmeso expression (either GEFmeso18-5 
or GEFmeso RNAi) did not modify the Ras85D RNAi phenotypes in the ACV or PCV 
(Appendix C).  This may indicate that GEFmeso and Ras85D do not interact in the cross 
vein regions of the wings.  Alternatively, the penetrance and severity of the Ras85D 
phenotype may be too high to detect a synergistic interaction.   
 
 
In contrast, simultaneous reduction of GEFmeso (GEFmeso18-5 or GEFmeso RNAi) and 
Ras85D enhanced the Ras85D loss of vein phenotype (Table 22).  I found enhancement 
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of the Ras85D RNAi phenotype was most profound in regions of the wing where Ras85D 
has the weakest phenotypes.  For example, in females, where there is weaker expression 
of Ras85D RNAi, removing a copy of GEFmeso increases the loss of L2 vein phenotype 
by 4-fold whereas in males, where Ras85D RNAi is stronger, the loss of vein phenotype 
increased only 2-fold (Table 22 and Appendix C).  In a second example, L2 had the 
weakest phenotype RNAi Ras85D and after removing a copy of GEFmeso18-5, the 
phenotype increased 4-fold.  In L5, where RNAi Ras85D had the most severe phenotype, 
removing a copy of GEFmeso18-5 did not change the phenotype (Table 22).  These results 
indicate a global, synergistic relationship between GEFmeso and Ras85D in the 
longitudinal veins. 
 
Table 22 GEFmeso Enhances the Ras85D Phenotype in the Longitudinal Veins 
 
 Loss of Vein Phenotype 
(%) 
  
Genotype Sex L2 L3 L4 L5 N T (oC) 
Bx-G4>UAS-Ras8D.RNAi; 
18-5/+ 
F 60 93.3 100 93.3 30 25 
M 66.6 94.4 100 94.4 18 
Bx-G4>UAS-GEFmeso 
RNAi; UAS-Ras85D.RNAi 
F 47.5 100 100 100 40 25 
M 66.6 94.4 100 94.4 18 25 
Bx-G4>UAS-Ras85D.RNAi F 12.8 76.9 89.7 97.5 58 25 
M 29.7 100 100 100 60 
18-5/+ M 0 0 0 0 58 25 
F 0 0 0 0 60 
Bx-G4>GEFmeso.RNAi F 0 0 0 0 107 25 
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In summary, I tested for interactions between GEFmeso and four genes in the wing using 
an RNAi-loss of function approach.  I found distinct differences in the interaction profiles 
between GEFmeso and other GTPase genes across microenvironments in the wing (Table 
23). This genetic data provides evidence that GTPase signaling networks exhibit 
intercellular variation within an otherwise uniform epithelium. 
 
Table 23 Interactions between GEFmeso and GTPases Across the Wing 
 
Gene 1 Rala Rac1 Mtl Ras85D 
ACV A WI I NI, NI 
PCV A WI I NI 
L2 NI NI NI S 
L3 NI NI NI S 
L4 NI NI NI S 
L5/Posterior 
to L5 
NI NI I WS 
L1/L2 NI NI NI NI 
L2/L3 NI NI NI NI 
L3/L4 NI NI NI NI 
L4/L5 NI NI NI NI 
 
Antagonistic (A): One gene suppresses the phenotype of the other 
Synergistic (S): One gene enhances the phenotype of the other 
I: Interaction between two genes that cannot be characterized as antagonistic or 
synergistic 
NI: No interaction  
NI: GEFmeso has a phenotype that is not modified by Gene 2 
NI: Gene 2 has a phenotype that is not modified by GEFmeso 
W: Weak interaction (interaction, synergistic, or antagonistic) 
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CHAPTER FOUR: DISCUSSION 
 
There is mounting evidence that the concept of GTPase signaling as a series of linear or 
branched pathways connected by ‘cross talk’ is too simplistic.  A more accurate reflection 
of cellular events may be one in which GTPases act within the context of networks with 
multiple nodes and points of connectivity.  In this network model, some nodes are more 
important for network function than others (i.e. have non-redundant functions), and 
mutations affecting nodes that are critical for network function are more likely to disrupt 
the network (i.e. have phenotypes) than less essential nodes (Costanza et al, 2010).  
While variation between GTPase networks has been explored at a sub-cellular level, such 
variation is unknown in a tissue.  At the subcellular level in migrating MEFs, RhoA 
activation is localized within the first two micrometers from the membrane at sites of 
protrusion, whereas Rac1 and Cdc42 are activated at and beyond two micrometers from 
the membrane (Pertz, 2010; Kiyokawa et al, 2011; Machacek et al, 2009).  Several other 
recent studies examine subcellular GTPase signaling patterns (Machacek et al, 2009; 
Aoki et al 2004; Itoh et al, 2002; Kurakowa et al, 2009; Pertz, 2010; Pertz et al, 2006), 
but none have attempted to examine intercellular GTPase network signaling in similar 
developmental contexts in vivo.  Thus, comparing signaling networks between similar 
cells is the next step to understanding the developmental roles of GTPases.  
 
GEFmeso is a Guanine Nucleotide Exchange Factor that Interacts with GTPases in 
Multiple Developmental Contexts 
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Previous studies have established that the signaling program of a GTPase, and its 
interacting partners are not only cell-type dependent but also are tightly regulated 
spatially and temporally.  Although in vitro assays give insight into intermolecular and 
intramolecular interactions on a protein domain level, identifying and exploring the 
variation in GTPase interactions in vivo is important to validate their signaling activities.  
To do this, we investigated a mutant, 18-5, that interacts genetically with Rho1 during leg 
morphogenesis and embryogenesis (Halsell et al, 2000; Maggie, 1999; Strutt, 1997).  
Here I provide evidence demonstrating that 18-5 is a mutation in the guanine nucleotide 
exchange factor GEFmeso.  I show that a GEFmeso transgene can functionally rescue 
mutant phenotypes observed in 18-5 homozygous animals.  The phenotypes rescued were 
lethality, an anteriorally everted wing phenotype, and leg malformation, indicating 
GEFmeso is vital for embryonic and adult development.   The role of the GEFmeso short 
transcript remains to be investigated.  The short transcript lacks the DHPH domains, 
which would confer GEF activity, but does retain the Ral GTPase binding region and 
other protein binding motifs (Schmidt and Hall, 2002; Blanke and Jackle, 2006).  I did 
not attempt to perform the 18-5 rescue with the short transcript, but it would be 
interesting to determine if it has functions that overlap with the long transcript.  However, 
the long and short transcripts are expressed at distinct, non-overlapping time points, and 
therefore it is unlikely that GEFmeso short could function in place of the long transcript.   
 
 
The GEFmeso long protein is active in multiple tissues (wing, embryonic tissue, and leg) 
and has genetic and/or physical interactions with several GTPases.  GEFmeso binds 
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physically to GTP-bound Rala and nucleotide depleted Cdc42 in vitro, suggesting 
GEFmeso is an exchange factor for Cdc42 and an effector of Rala.  However, in vitro 
binding studies reveal GEFmeso does not bind to Rho1 (Blanke and Jackle, 2006).  
Therefore it is likely that GEFmeso communicates with Rho1 indirectly.  Previously it 
was unknown if GEFmeso interacts with Rala in vivo.  However, I have shown an 
antagonistic relationship between GEFmeso and Rala in the anterior cross vein regions of 
the wing.  The in vivo relationship between GEFmeso and Cdc42 remains to be 
determined. 
 
 
GEFmeso shares DH sequence similarity with Dbl and Dbl’s Big Sister (Dbs), both of 
which are Rho1 and Cdc42 exchange factors (Blanke and Jackle, 2006), suggesting 
GEFmeso may be an activator of Rho1 and Cdc42.  In DBS, the PH is required for the 
DH domain to bind the GTPase (Schmidt and Hall, 2002; Rossman et al, 2002).  The PH 
domain has traditionally been thought to mediate binding to the phosphoinositides of the 
membrane, but more recent studies have shown the PH domain also increases the 
catalytic activity of the DH domain and in some cases may interact directly with the 
GTPase (Baumeister et al, 2006).  Sequencing analysis of the GEFmeso18-5 mutation 
reveals a deletion that retains the DH domain, but loses approximately half of the PH 
domain resulting in a frameshift and premature truncation of the protein.  The 
consequences of the GEFmeso18-5 deletion are likely reduced efficiency of the catalytic 
domain and reduced ability to localize to the plasma membrane. 
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GTPases have microenvironment-dependent interactions 
 
 GEFmeso interacts genetically and biochemically with multiple GTPases in a variety of 
developmental contexts.  Thus GEFmeso is a good starting point to examine potential 
variation in the intracellular structure of GTPase networks.  To address these questions, I 
first surveyed the requirement for a subset of GTPases and a few regulators in different 
microdomains in the wing.  I identified a new global regulator of vein fate, Ras85D, by 
expressing RNAi against Ras85D through out the wing.  RNAi against Ras85D caused 
loss of vein tissue from all veins in the wing.  This result was not surprising since loss of 
function Ras mutants result in loss of veins and Ras signaling can be detected in 
developing wing veins (Blair, 2007; Baonza and Garcia-Belido, 1999; Ciapponi et al 
1999).  As expected, RNAi against Egfr (a second global designator of vein fate) 
disrupted most microdomains of the wing.  The phenotypes of RNAi animals was more 
complex than that of RNAi Ras85D.  Egfr suppressed vein material in intervein region 
L2/L3 but promoted vein formation in the ACV, PCV and longitudinal veins 3-5.  This 
result is consistent with reports that Egfr signaling switches on and off in the veins at 
different time points in development (Martin-Blanco et al, 1999) and an RNAi approach 
could result in opposite phenotypes depending on the temporal expression pattern of the 
Gal4 driver.  Ras85D is downstream of Egfr and both are required for wing vein 
development (Sotillos and Campuzano, 2000; Marcoux and Vuori, 2005; Munoz-
Descalzo et al, 2007).  The role of GEFmeso in the Egfr-Ras signaling pathway remains 
to be investigated.  Although, we did not investigate the interaction between GEFmeso 
and Egfr, I show that GEFmeso interacts with Ras in four wing microdomains.  One 
interesting avenue to explore would be the interaction between Ras85D and Egfr in the 
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L2/L3 intervein region.  This intervein region was the only region where ectopic veins 
were observed in an Egfr RNAi animal.  Egfr acts upstream of Ras, and therefore the 
contrasting phenotype is unexpected.  
 
 
I asked if proteins required for wing vein development exhibit consistent behavior across 
the wing epithelium.  In general we found that proteins behaved consistently across the 
wing, however some proteins showed microenvironment variation in behavior.  Examples 
are Rho1 and Mtl which suppressed vein development in some microenvironments and 
promoted veins in others.  Rac1 and Mtl both promoted vein formation in the cross veins 
but suppressed veins around longitudinal vein five.  It is worth mentioning that the Rac1 
RNAi phenotype in the ACV had low penetrance, however it did interact with 
GEFmeso18-5 resulting in a substantial loss of ACV tissue.  Furthermore, both Mtl and 
Rac1 showed similar interactions with GEFmeso.  Phenotypes for both proteins were 
enhanced in the anterior and posterior cross veins when GEFmeso was simultaneously 
reduced.  However, Rac1 did not interact genetically with GEFmeso in the longitudinal 
vein five microdomain while Mtl did.   GEFmeso failed to interact with Rac1 in the 
L2/L3 intervein region or in the longitudinal veins four and five.  
 
 
I also showed that GEFmeso interacts with Rala and Ras85D in a microenvironment-
dependent manner.  The interaction between GEFmeso and Rala is antagonistic in the 
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cross veins, however, I failed to detect any genetic interaction in the intervein region 
between L2/L3, a microenvironment where GEFmeso suppresses vein formation.  
Ras85D and GEFmeso Interact Globally in the Wing 
 
Finally, we show that GEFmeso interacts globally with Ras85D in the wing and the 
interactions are microenvironment dependent.  Both proteins are required for anterior 
cross vein formation but there was no interaction between them in this region of the wing.  
It is possible that a synergistic interaction could not be detected due to the high 
penetrance of the Ras85D phenotype.  However, an antagonistic relationship between 
Ras85D and GEFmeso can be ruled out since suppression of the RNAi Ras85D 
phenotype was not observed.  Alternatively, Ras85D and GEFmeso may operate in non-
interacting networks in the anterior cross vein.  The interaction between GEFmeso and 
Ras in the longitudinal veins was an unexpected result because animals expressing RNAi 
against GEFmeso, or GEFmeso18-5 homozygotes do not have longitudinal vein defects.  
However, reduced GEFmeso signaling consistently enhanced the Ras85D loss of vein 
phenotype.  The interaction is weak in longitudinal vein five; the longitudinal vein where 
the Ras85D phenotype is strongest.  One possible explanation for the observations is that 
GEFmeso activity is redundant in this region of the wing and a phenotype is only 
observed when additional genes (Ras85D) are also knocked down.  In summary, the 
interaction data for GEFmeso and Rala, Rac1, Mtl and Ras85D provide evidence for 
microenvironment-dependent variation in GTPase signaling networks in specific domains 
of the wing, and reveal intercellular variation in GTPase signaling within an otherwise 
uniform epithelium. 
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Summary 
 
I characterized the genetic interactions of GEFmeso, a gene that interacts with multiple 
GTPases, within a single tissue.  I have shown that despite structural uniformity across 
the wing, the signaling programs utilized vary in different microenvironment.  I have also 
shown that GTPase signaling pathways can have opposite phenotypic effects depending 
on microenvironment.  Thus I have demonstrated that the ways GTPase networks are 
constructed and interconnected are not uniform across an epithelium.  This work adds to 
existing studies that have demonstrated subcellular variation in GTPase networks and 
points to the complexity of understanding protein network organization at a subcellular 
and intercellular level.  Ultimately, this work has relevance to human pathology such as 
cancer, where signaling networks unique to the cancer and localized to a specific niche in 
the tumor (i.e. stem cell niche), may be targeted with minimum toxicity to cells. 
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APPENDIX A: RESULTS OF SINGLE RNAI EXPRESSION DATA 
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Genotype/T(oC)/ 
Stocks Used 
Se
x 
N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/L4 L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
Ras64B.dsRNA/25/ 
BL8860/BL29318 
F 
 
99 88 Loss 0 <1 1 1 1 4 0 0 0 0 0 
Ect. 0 4 0 3 0 0 0 0 0 0 0 
M 100 23 Loss 27 14 0 0 0 17 0 0 0 1 0 
Ect. 0 0 0 1 24 15 0 10 1 3 11 
Bx-G4>UAS-
Ras64B.dsRNA/29/ 
BL8860/BL29318 
F 
 
60 95 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 1.6 1.6 1.6 0 0 0 0 0 
M 59 20 Loss 6.7 20.3 0 0 0 0 0 0 0 0 0 
Ect. 0 0 5 3.3 33.8 52.5 0 3.3 0 1.6 13.5 
Bx-G4>UAS-
RhoGAPp190. 
RNAi/25/BL 8860, BL 
6430 
F 
 
137 99 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 1 0 0 0 0 0 0 0 0 0 
M 114 94 Loss 7 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-G4>UAS-
RhoGAPp190. 
RNAi/29/BL 8860, BL 
6430 
F 
 
60 96.6 Loss 0 1.6 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 55 46.5 Loss 46.5 0 0 0 10.3 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-G4>UAS-
Dcr2;UAS-
p190.TRiP/25/BL 
25706/BL 31070 
F 
 
57 91.3 Loss 3.8 3.8 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 1.7 0 0 
M 61 6.5 Loss 62.2 21 0 0 1.6 1.6 0 0 0 0 0 
Ect. 0 0 1.6 0 6.5 0 0 1.6 0 0 1.6 
Bx-G4>UAS-
Ras85D.TRiP/18/ BL 
8860, BL 29319  
F 
 
56 10.7 Loss 62.5 82.1 0 17.
8 
10.7 23.2 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 61 0 Loss 96.7 96.7 4.9 37.
7 
21.3 1.6 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
 
Numbers represent percents of total wings scored that had the indicated defect.  N is the sample of wings scored for defects 
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
Ras85D.TRiP/25/ BL 
8860, BL 29319 
F 
 
39 0 Loss 97.4 97.4 12.8 76.9 89.7 97.4 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 50 0 Loss 100 97.8 29.7 100 100 100 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-G4>UAS-
Dcr2;UAS-
RhoGEF2.TRiP/25/B
L 25706, BL 31239 
F 
 
57 49.1 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 24.5 0 3.5 14 0 0 5.2 0 0 0 
M 56 25 Loss 0 3.5 0 0 0 0 0 0 0 0 0 
Ect. 0 19.6 1.7 8.9 23..2 5.3 1.7 28.5 0 1.7 8.9 
Bx-G4>UAS-
RhoGEF2.TRiP/25/ 
BL8860, HMS01118 
F 
 
58 17.2 Loss 0 10.3 0 0 0 0 0 0 0 0 0 
Ect. 0 55.1 0 1.7 27.5 0 0 3.4 0 1.7 0 
M 56 5.3 Loss 3.5 33.9  1.7 0 1.7 0 0 0 0 0 
Ect. 1.7 32.1 1.7 5.3 53.5 37.5 0 12.5 0 3.5 16 
Bx-G4>UAS-
Rac1.TRiP/25/ BL 
8860, BL 28985 
F 
 
104 96 Loss 0 <1 0 0 0 0 0 0 0 0 0 
Ect. 0 <1 0 0 <1 0 0 0 0 0 0 
M 95 65.2 Loss 3.1 14.7 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 9.5 13.4 0 0 0 0 29.8 
Bx-G4>UAS-
Rac1.TRiP/29/ BL 
8860, BL 28985 
F 
 
50 72 Loss 0 0 6 2 14 0 0 0 0 0 0 
Ect. 6 10 0 0 4 4 0 0 0 0 0 
M 45 13.3 Loss 6.6 6.6 2.2 0 2.2 15.5 0 0 0 0 24.5 
Ect. 2.2 0 2.2 0 40 53.5 0 0 0 2.2 4.4 
Bx-G4>UAS-
Rho1.dsRNA/25/ BL 
8860, BL 9910 
F 
 
95 8.4 Loss 53.7 13.7 0 0 0 0 0 0 0 0 0 
Ect. 1.1 66.3 0 1.5 0 0 0 13.7 0 1.1 0 
M 38 11.8 Loss 41.2 20.6 0 1.5 1.5 4.4 0 0 0 0 0 
Ect. 2.9 50 1.5 10.3 16.2 0 0 14.7 2.9 7.4 0 
Numbers represent percents of total wings scored that had the indicated defect.  N is the sample of wings scored for defects 
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
Rho1.dsRNA/18/ BL 
8860, BL 9910 
F 
 
57 26.3 Loss 54.3 8.7 0 0 0 5.2 0 0 0 0 0 
Ect. 0 28 3.5 3.5 5.2 0 5.2 10.5 0 0 0 
M 46 23.9 Loss 39.1 10.8 0 0 0 0 0 0 0 0 0 
Ect. 0 26.2 6.5 2.1 6.5 4.3 0 21.7 0 0 0 
Bx-G4>UAS-
Mtl.TRiP/25/ 
BL8860/ BL 28622 
F 
 
60 80 Loss 0 10 0 0 0 1.6 0 0 0 0 0 
Ect. 0 1.6 0 0 5 0 0 0 0 0 0 
M 60 48.3 Loss 8.3 18.3 0 0 0 01.6 0 0 0 0 0 
Ect. 0 0 0 0 10 26.6 0 0 0 0 0 
Bx-G4>UAS-
Mtl.TRiP/29/ 
BL8860/ BL 28622 
F 
 
43 93 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 4.6 0 0 2.3 0 0 0 0 2.3 0 
M 57 26.3 Loss 3.5 17.5 0 0 0 1.7 0 0 0 0 0 
Ect. 0 0 0 0 38.5 59.6 0 0 0 0 1.7 
Bx-G4>UAS-
Cdc42.TRiP/18/ 
BL8860/ BL 28021 
F 
 
10 0 Loss 50 50 0 0 0 0 0 0 0 0 0 
Ect. 40 0 0 0 40 0 0 40 0 0 0 
M NS  Loss            
Ect.            
Bx-G4>UAS-
GEFmeso 
Long/18/BL8860, 
Line 75B2 
F 
 
53 1.8 Loss 69.8 88.6 0 0 0 0 0 0 0 0 0 
Ect. 0 3.7 0 0 9.4 3.7 0 0 0 0 0 
M 42 0 Loss 100 100 0 0 0 14.2 0 0 0 0 0 
Ect. 0 0 28.5 23.8 45.2 26.1 0 2.3 0 0 0 
18-5/18-5/ 25 F 
 
13 53.8 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 23 15.3 0 0 0 0 0 30.7 0 0 0 
M 25 36 Loss 4 0 0 0 0 0 0 0 0 0 0 
Ect. 28 24 0 0 0 0 0 40 0 0 0 
Numbers represent percents of total wings scored that had the indicated defect.  N is the sample of wings scored for defects 
NS: Animals were too malformed and phenotype could not be scored
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
CG30115.RNAi/ 25/ 
BL 8860, v39952 (I) 
F 
 
107 95.3 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 4.6 0 0 0 0 0 0 0 0 0 0 
M NA  Loss            
Ect.            
Bx-G4>UAS-
G30115.RNAi/ 29/ 
BL 8860, v39952 (I) 
F 
 
59 67.7 Loss 0 1.6 0 0 0 0 0 0 0 0 0 
Ect. 28.8 1.6 0 0 1.6 1.6 0 0 0 0 0 
M NA  Loss            
Ect.            
Bx-G4>UAS-Dcr2; 
UAS-CG30115.RNAi/ 
29/ BL 25706, v39952 
(I) 
F 
 
59 27.1 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 67.7 1.6 1.6 6.7 0 0 0 0 0 0 0 
M NA  Loss            
Ect.            
Bx-G4>UAS-Dcr2; 
UAS-CG30115.RNAi/ 
25/ BL 25706, v39952 
Line I2 
F 
 
60 41.6 Loss 0 1.6 0 0 0 0 0 0 0 0 0 
Ect. 30 28.3 0 0 1.6 0 0 10 3.3 0 0 
M 60 40 Loss 0 1.6 0 0 0 0 0 0 0 0 0 
Ect. 41.6 10 0 1.6 5 1.6 0 6.6 0 0 0 
Bx-G4>UAS-
CG30115.RNAi/ 29/ 
BL 8860, v39952 Line 
I2 
F 
 
58 63.7 Loss 3.4 1.7 0 0 0 0 0 0 0 0 0 
Ect. 20.6 6.8 0 0 3.4 0 0 1.7 0 0 0 
M 59 6.7 Loss 1.6 0 0 0 0 1.6 0 0 0 0 0 
Ect. 22 15.2 1.6 0 71.1 16.9 0 1.6 0 5 54.2 
Bx-G4>UAS-
Rala.RNAi/25/BL 
8860, Bl 29580 
F 
 
95 0 Loss 94.2 96.5 ND ND ND ND ND ND ND ND ND 
Ect. 0 0 ND ND ND ND ND ND ND ND ND 
M 99 0 Loss 89.4 94.7 ND ND ND ND ND ND ND ND ND 
Ect. 0 0 ND ND ND ND ND ND ND ND ND 
Numbers represent percents of total wings scored that had the indicated defect.  N is the sample of wings scored for defects 
NA: Insertion on X.  Males are not the relevant genotype. ND: Not determined 
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
Rala.RNAi/18/BL 
8860, BL 29580 
F 
 
59 67.7 Loss 0 28.8 0 0 0 0 0 0 0 0 0 
Ect. 0 1.6 0 1.6 3.2 0 0 0 0 0 0 
M 47 4.2 Loss 46.8 91.4 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-G4>UAS-
Egfr.RNAi/25/BL 
8860, BL 25781 
F 
 
38 0 Loss 100 97.3 0 100 86.6 92.1 0 0 0 0 0 
Ect. 0 0 0 0 2.6 0 2.6 0 0 2.6 0 
M NS  Loss            
Ect.            
Bx-G4>UAS-
Egfr.RNAi/18/BL 
8860, BL 25781 
F 
 
47 0 Loss 100 82.9 0 82.7 17 36.1 0 0 0 0 0 
Ect. 0 6.3 0 4.2 8.5 0 12.7 29.7 0 0 0 
M 42 0 Loss 100 45.5 13.6 100 100 100 0 0 0 0 0 
Ect. 0 4.5 0 0 0 0 0 0 0 4.5 0 
Bx-G4>UAs-
Roughened.RNAi/25/
BL8860, BL 29434 
F 
 
60 98.3 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 1.6 0 0 0 
M 58 68.9 Loss 3.4 1.7 0 0 0 0 0 0 0 0 0 
Ect. 0 0 1.7 1.7 5.3 5.1 0 0 0 1.7 12.7 
Numbers represent percents of total wings scored that had the indicated defect.  N is the sample of wings scored for defects 
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APPENDIX B: RESULTS FOR SINGLE OVER-EXPRESSION RESULTS AND CONTROLS 
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
w[1118]/25 F 
 
50 100 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 49 93.8 Loss 6.1 2 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
w[1118]; 18-5/+/29 F 
 
60 70 Loss 8.3 1.6 0 0 0 0 0 0 0 0 0 
Ect. 5 0 0 0 0 0 11.6 1.6 1.6 0 6.6 
M 60 88.3 Loss 5 0 0 0 0 0 0 0 0 0 0 
Ect. 5 0 0 0 0 0 0 0 0 0 1.6 
w[1118]/18 F 
 
58 98.2 Loss 1.7 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 60 96.6 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 3.3 0 0 0 
Bx-G4>UAS-
RhoGAPp190/18 
F 
 
59 96.6 Loss 0 1.60 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 58 45.6 Loss 46.5 0 0 0 10.3 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
W[1118] ;18-5/+/25 F 
 
61 98.2 Loss 1.7 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 60 96.6 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 3.3 0 0 0 
Bx-G4>UAS-
GEFmeso Long/25/ 
BL 8860, Line 75B2 
F 
 
20 0 Loss 100 90 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 ND ND ND ND ND ND ND ND 
M 18 0 Loss 100 94.4 0 0 5.5 33.3 0 0 0 0 0 
Ect. 0 0 5.5 0 5.5 16.6 0 5.5 5.5 0 5.5 
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Genotype/T(oC) Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-G4>UAS-
Rala.RNAi; 18-5/25 
F 
 
53 13.2 Loss 49 71.6 0 0 0 38 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M ND  Loss            
Ect.            
Bx-G4>UAS-
Rala.RNAi; 18-5/18 
F 
 
70 87.1 Loss 1.4 2.8 0 0 0 0 0 0 0 0 0 
Ect.  2.8 0 0 0 2.8 0 0 0 0 0 
M ND  Loss            
Ect.            
Bx-G4>UAS-
Rala.RNAi ; UAS-
CG30115 RNAi (I)/18 
F 
 
60 96.6 Loss 0 0 0 0 0 0 0 0 0 0 0 
Ect. 0 17.8 0 0 1.7 0 5.3 5.3 0 0 0 
M NA  Loss            
Ect.            
Bx-G4>UAS-
Rala.RNAi ; UAS-
CG30115 RNAi (I)/25 
F 
 
36 0 Loss 5.5 75 11.1 2.7 5.5 50 0 0 0 0 0 
Ect. 11.1 0 0 0 5.5 0 0 8.3 0 0 0 
M NA  Loss            
Ect.            
Bx-G4>UAS-
Rac1.RNAi; 18-
5/+/25 
F 
 
48 72.9 Loss 0 0 0 0 0 0 0 2 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 57 26.3 Loss 22.8 24.5 0 0 0 0 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 7 26.3 
Bx-G4>UAS-
Mtl.RNAi; 18-5/+/25 
F 
 
53- 96 Loss 0 1.9 0 0 0 0 0 0 0 0 0 
Ect. 0 3.9 0 0 0 0 0 0 0 0 0 
M 59- 12.2 Loss 20.3 37.2 0 0 0 1.7 0 0 0 0 0 
Ect. 0 3.3 0 0 6.7 27.1 0 0 0 8 33.8 
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Genotype/T(oC)/ 
Stocks Used 
Sex N WT Defect ACV PCV L2 L3 L4 L5 L1/L2 L2/ 
L3 
L3/ 
L4 
L4/ 
L5 
Poster
ior to 
L5 
Bx-UAS-
Ras85D.RNAi ; 18-
5/+/25 
F 
 
30 0 Loss 86.6 86.6 60 93.3 100 93.3 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 18 0 Loss 100 100 66.6 94.4 100 94.4 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-UAS-
Ras85D.RNAi ; 18-
5/+/18 
F 
 
49 8.1 Loss 71.4 81.6 2 40.3 42.8 32.6 2 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M 42 0 Loss 100 97.6 0 73.8 14.2 28.5 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
Bx-G4>UAS-
Ras85D.RNAi; UAS-
CG30115.RNAi (I)/ 
25 
F 
 
40 0 Loss 95 97.5 47.5 100 100 100 0 0 0 0 0 
Ect. 0 0 0 0 0 0 0 0 0 0 0 
M NA  Loss            
Ect.            
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